11.2 Bipolar Disorder

Bipolar Disorder

Introduction

Bipolar disorder involves the occurrence of one or more manic or hypomanic episodes, often alongside a history of major depressive episodes. It is a long-term condition marked by recurring episodes and periods of remission. Mood disturbances may present as mania, hypomania, or depression, and these episodes can include specific features, such as mixed moods. The duration between episodes may vary, ranging from extended periods of stability to rapid cycling, and they may occur with or without psychotic symptoms. The impact on individuals and their families can be severe, leading to significant disability and an elevated risk of suicide. Early and accurate diagnosis, along with appropriate treatment, is critical to avoiding complications and achieving the best treatment outcomes.

The onset of bipolar disorder typically occurs in the late 20s, which is around 15 years earlier than the onset of unipolar depression. However, it can also manifest during adolescence. In individuals who are predisposed, mania may be triggered by a variety of medications, such as antidepressants, corticosteroids, ACE inhibitors, dopaminergic drugs, as well as by certain stimulant and illicit substances.

Acute Mania

Acute mania is characterized by a sudden onset of symptoms, including a persistently elevated, expansive, or irritable mood, along with rapid speech, racing thoughts, and an increase in activity levels. Individuals often require less sleep, may develop grandiose ideas, engage in risky behaviours like excessive spending, and experience heightened sexual drive and activity. When psychotic symptoms are present, the episode is considered severe. For a diagnosis of mania, symptoms must be evident for most of the day, cause significant functional impairment, and last for at least a week. However, if hospitalization is necessary due to the severity of symptoms, a diagnosis can be made regardless of symptom duration.

Hypomanic Episodes

A hypomanic episode shares many symptoms with a manic episode, but the symptoms are less intense and do not significantly disrupt daily functioning. These symptoms typically persist for a minimum of four consecutive days and are present for the majority of each day. Unlike mania, hypomania does not involve psychotic features.

Depressive Episodes

Depressive episodes last for at least 2 weeks and must include a depressed mood, or a loss of interest or pleasure, for most of the day. The episode must cause significant distress or impair the person’s functioning; during depressive episodes, there is a high risk of suicide. While most symptoms overlap with those of major depression, patients with bipolar depression are more likely to have atypical depressive features (eg excessive sleeping or eating), psychomotor slowing, psychotic features or mixed features (ie manic or hypomanic features interspersed in the depression). Most patients experience at least one depressive episode before developing a first episode of mania or hypomania. Depressive episodes are the predominant mood episode for most patients with bipolar disorder, especially those with bipolar II disorder. Patients with bipolar disorder also frequently experience periods of subthreshold depressive symptoms between the major mood episodes.

Mixed features describes the simultaneous experience of symptoms opposite to the predominant state (eg during a manic episode, patients also experience depressive symptoms). Mixed features can occur during a manic, hypomanic or depressive episode.

Bipolar Subtypes

Bipolar disorders are divided into several categories, including bipolar I disorder, bipolar II disorder, and other specified or unspecified bipolar and related disorders. Bipolar I disorder is defined by the presence of at least one manic episode, while bipolar II disorder is characterized by at least one hypomanic episode, with both types typically involving major depressive episodes.

Symptoms during manic episode

Mania is marked by excessive speech and motor activity, a decreased need for sleep, grandiose or paranoid thoughts, elevated or irritable mood, impaired judgement, aggressive behavior, and hostility. It may also involve reckless spending and, at times, promiscuity. In the less severe state of hypomania, individuals may face social difficulties, such as heightened activity levels, unfinished tasks, irritability, wearing overly bright or messy clothing, poor decision-making, and an increase in sexual interest. Individuals with bipolar disorder can subsequently experience a shift to depression, which may last for several months.

Treatment of Bipolar Disorder

Counselling, psychotherapy and drug therapy are beneficial for treating bipolar disorders. The main class of drugs used to manage the symptoms of bipolar disorder are the mood stabilisers. The major drugs are:

  • lithium;
  • certain antiepileptic drugs, e.g. carbamazepine, valproate, lamotrigine; and
  • some antipsychotic drugs (second generation), e.g. olanzapine, risperidone, quetiapine, aripiprazole, brexpiprazole, cariprazine.

Certain other agents may offer benefits in managing bipolar disorder. Benzodiazepines can help by promoting calmness, sleep, and reducing anxiety. Memantine and amantadine have potential to alleviate depression and cognitive issues, while ketamine may be useful for addressing suicidal thoughts. The use of antidepressants in bipolar disorder remains debated, as they are typically prescribed alongside antimanic medications. This is because, in some individuals, antidepressants may trigger or intensify manic episodes. Antipsychotic drugs, benzodiazepines and some antiepileptic drugs are useful for sedation and control of the mania symptoms, and antidepressants with lithium in the depressive phases for at least 6 months.

Lithium

Lithium is also known as a mood stabiliser. It is used as first-line treatment for acute mania and prevention of recurrences of manic episodes.

Mechanism of Action

The exact mechanism by which lithium functions remains unclear. Research has shown that manic patients may experience a significant increase in intracellular sodium levels, by as much as 200%. Both lithium and sodium are actively transported across cell membranes; however, lithium is less effectively expelled from the cell compared to sodium. Lithium interferes with sodium’s role in various physiological functions. It inhibits or slows down several cellular processes, including G-protein receptor coupling, adenylate cyclase activity, phosphoinositol signalling, and various kinase activities, which are involved in neuroprotective pathways. Lithium also reduces neurotransmitter release, particularly dopamine, enhances the turnover of noradrenaline and serotonin (5-HT) in the brain, and diminishes the sensitivity of postsynaptic receptors. This modulation helps to normalize the presumed hyperactive catecholamine systems observed in manic states. In individuals who are not experiencing mania, lithium exerts minimal effects.

Indications

Lithium is primarily used for the prevention of manic and depressive episodes in individuals with bipolar affective disorder. It is also utilized to manage acute mania and is sometimes employed as an adjunct therapy in schizophrenia and treatment-resistant depression. Clinically, lithium requires careful handling due to its narrow therapeutic index, necessitating close monitoring. It has little to no psychotropic effect in individuals who do not experience mood episodes.

Pharmacokinetics

Except for the slow-release formulations, lithium is rapidly absorbed, with peak plasma concentrations occurring within 1 to 3 hours after administration. It has a prolonged half-life: approximately 24 hours in adults, 18 hours in adolescents, and up to 36 hours in elderly patients. As a result, steady-state plasma concentrations are typically achieved within 5 to 7 days. Lithium is excreted unchanged via the kidneys and undergoes partial reabsorption in the proximal tubules alongside sodium.

Therapeutic Drug Monitoring (TDM)

Lithium’s therapeutic window is narrow, and concentrations exceeding the therapeutic range by just 1.5 times can result in severe toxicity. Therefore, regular monitoring of plasma levels is essential. Blood samples are typically collected 8–12 hours after the last dose to assess trough levels. For bipolar disorder, therapeutic plasma concentrations are generally between 0.8 and 1.2 mmol/L during acute treatment and 0.6 to 0.8 mmol/L for maintenance therapy. Clinical responses usually manifest within 1 to 3 weeks. Monitoring is conducted weekly during dosage adjustments, and once stabilized, it occurs every three months, with more frequent assessments during periods of illness or other changes in health status.

Drug Interactions

Lithium interacts with various medications, especially those that influence kidney function, such as diuretics, sodium compounds, and non-steroidal anti-inflammatory drugs (NSAIDs). It can also interact with medications affecting thyroid function or serotonin levels (5-HT). Changes in lithium’s metabolism or excretion due to other drugs can also lead to pharmacokinetic interactions.

Adverse Effects

Lithium’s side effects include hand tremors, increased thirst, nausea, frequent urination, diarrhea, and an irregular heartbeat. Over long-term use, it may cause acne, psoriasis, hypothyroidism, weight gain, hyperparathyroidism, and kidney damage. A notable side effect is nephrogenic diabetes insipidus, where lithium reduces the effectiveness of antidiuretic hormone in the kidney’s distal tubules, leading to excessive urination. Early signs of lithium toxicity include confusion, vomiting, tremors, slurred speech, and drowsiness. As toxicity worsens, symptoms such as blurred vision, seizures, severe tremors, uncoordinated movement, heart rhythm disturbances, and excessive urination can occur. Prolonged toxic levels may result in irreversible brain damage, and even relatively modest plasma levels can be life-threatening. Treating toxicity typically involves gastric lavage, forced diuresis, or dialysis.

Warnings and Contraindications

Caution is advised when using lithium in individuals with diabetes, hypothyroidism, goitre, psoriasis, pregnant or severely debilitated individuals, or those following a sodium-restricted diet. Lithium is contraindicated in patients with a history of lithium hypersensitivity, severe dehydration, significant kidney dysfunction, or during breastfeeding. Monitoring of calcium levels is recommended due to the risk of hyperparathyroidism.

Lithium levels can increase due to kidney dysfunction, diarrhea, vomiting, fluid or salt depletion, diuretic use, dehydration, low-sodium diets, excessive sweating, fever, or strenuous exercise. On the other hand, factors that may decrease lithium levels include a high intake of sodium chloride, sodium bicarbonate, potassium citrate, theophylline, or pregnancy.

👁️🎧 Listen & Watch the Lecture on Drugs for Bipolar Disorder (10 minutes)

Lecture Material:

COMMONWEALTH OF AUSTRALIA Copyright Regulations 1969 WARNING This material has been reproduced and communicated to you by or on behalf of James Cook University in accordance with section 113P of the Copyright Act 1969 (Act).

The material in this communication may be subject to copyright under the Act. Any further reproduction or communication of this material by you may be the subject of copyright protection under the Act. Do not remove this notice.

License

MD2012 - Medical Pharmacology Copyright © by Robi Islam; John Smithson; Shane MacDonald; and Karl McDermott. All Rights Reserved.